Primary Clinical Indications Peripheral Neuropathy: Effectively treats nerve damage caused by diabetes or chronic illness
Semaglutide is a GLP-1 receptor agonist licensed in the UK for type 2 diabetes mellitus and weight management Standard blood panels do not detect semaglutide levels as these are not routinely measured in UK clinical practice Ozempic typically reduces HbA1c by 1.01.5% and improves metabolic parameters including lipid profiles and liver enzymes Regular monitoring includes HbA1c every 36 months, annual renal and liver function tests, and assessment for gastrointestinal side effects Patients must inform all healthcare providers about Ozempic use, particularly before surgical procedures due to delayed gastric emptying Table of Contents Understanding Ozempic and Routine Blood Tests Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist licensed in the UK for the treatment of type 2 diabetes mellitus and, at higher doses under the brand name Wegovy, for weight management in specific patient groups
Competitive Gaps: Direct-to-consumer platforms cannot serve complex cases (Medical Economics, 2025)
Infusion Therapy Our IV infusion therapy treatments are designed to support hydration and overall wellness
Orca Bios BLA for Hematologic Malignancy Cell Therapy Orca-T Accepted by FDA With Priority Review October 7, 2025 Orca Bios BLA for Orca-T, an investigational allogeneic cell therapy product intended to treat various hematologic malignancies, including acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplastic syndromes (MDS), has been accepted by the FDA with priority review
